Pro Health Tips
Wednesday, 29 April 2020
FDA Appproved Ibrutinib-rituximab Combo for Leukemia After E1912 Trial
E1912, a phase 3 trial, showed ibrutinib plus rituximab combination as a new treatment option for untreated patients (aged 70 or younger) with chronic lymphocytic leukemia.
from Medindia Health News https://ift.tt/2ycaVSo
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
E1912, a phase 3 trial, showed ibrutinib plus rituximab combination as a new treatment option for untreated patients (aged 70 or younger) with chronic lymphocytic leukemia.
No comments:
Post a Comment